LACERO
9.6.2020 09:02:08 CEST | Business Wire | Press release
Lacero, a next generation governance technology provider for digital assets, today announced the launch of FlowOS, offering advanced transaction control and permissioning. FlowOS is now live with major cryptocurrency liquidity provider B2C2.
FlowOS enhances existing wallet and custody solutions, giving users direct, independent control of their policies, procedures and rules. A radically different solution, it is the first platform to leverage blockchain technology to create a decentralised, immutable security architecture by constructing policy from independently certified smart contracts.
Introducing real-time governance, traceability and auditability, it makes it impossible to substitute, manipulate or circumvent approved policies and procedures, and enables reliable exception-based processing with a combination of programmable rules, automated workflow procedures and human approvals.
B2C2 has selected Lacero for its best-in-class technology for governance, controls and procedures. B2C2’s integration of FlowOS, in combination with its existing integration of Fireblocks’ cutting-edge payments technology, will further enhance the firm’s settlement capabilities – the largest by some margin in the OTC markets – for the benefit of its clients.
This combination of technology platforms further demonstrates B2C2’s bank-grade security and compliance standards which, twinned with its award-winning technology and the tightest and most consistent pricing, has made it the OTC liquidity provider of choice to the largest institutional names in the industry.
B2C2’s settlement platform, enhanced by the decentralised, auditable solutions offered by Lacero and Fireblocks, is setting a market standard for straight-through-processing that is applicable to both cryptocurrency and traditional financial markets.
Rashid Hoosenally, CEO of Lacero, said: “We’re excited to be partnering with a proven industry leader who shares our vision for institutional-grade governance and controls. B2C2 strive to continuously optimise processes and tailor workflows, so we’re delighted that FlowOS has been selected to provide them with a secure, flexible enforcement platform that can support them as they grow the scale, speed and breadth of their offering.”
Max Boonen, Founder and Group CEO of B2C2, said: “B2C2’s mission to bring best practices to the trading of digital assets spans both execution and post-trade. The ability to streamline and automate both trading and settlement is the next frontier in our industry. Enhancing the B2C2 platform with Lacero’s innovative technology will allow us to better serve our clients and further scale our business as the go-to counterparty.”
Simon Heinrich, CIO and Group Head of Technology at B2C2, said: “Operational excellence and client service are at the heart of what we do at B2C2 as we are relied upon to provide institutional-grade liquidity 24/7. Given the trustless environment and irreversibility of transactions in the continuously traded and settled crypto markets, FlowOS represents a critical component of our offering as it enables controlled autonomy of our processes in a demonstrably secure way.”
-Ends-
About Lacero
Lacero develops innovative technology for governing and safeguarding digital assets and data. Its platform is underpinned by blockchain, certified smart contracts and highly secure cryptographic methods. Based in the UK, Lacero was awarded Best RegTech Policy Platform 2020
in Wealth and Finance International’s FinTech Awards. For more information on Lacero’s FlowOS platform, please visit https://www.lacero.io
About B2C2
Founded in 2015, B2C2 is the leading cryptocurrency liquidity provider. Awarded Cryptocurrency Innovation of the Year
in 2020 by FStech and Best Institutional Crypto Liquidity Provider
in 2019 by the readers of Profit & Loss, B2C2 bridges the gap between traditional financial and cryptocurrency markets. The company is trusted by brokerages, exchanges, banks and fund managers to provide 24/7 liquidity. Headquartered in the UK, with offices in London, Jersey City and Tokyo, the firm is privately held. For more information, please visit https://www.b2c2.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom